Unfortunately, despite the rationale, the clinical use of ibrutinib, a Bruton tyrosine kinase inhibitor effective on ITK signaling, showed limited efficacy in PTCL in a pivotal trial (67). This evidence concerns the gene ITK and mature T-cell and NK-cell non-Hodgkin lymphoma.